SFRP1 and pancreatic neoplasm: In pancreatic cancer, our in silico analysis for SFRP1 revealed favorable overall survival of those patients exhibiting low DNA methylation in the core CpG island (CGI2), highlighting the potential clinical impact of SFRP1 CpG site-dependent promoter methylation as a prognostic or predictive biomarker.